Miles Nunn
Technik-/Wissenschafts-/F&E-Leiter bei AKARI THERAPEUTICS, PLC
Vermögen: - $ am 31.07.2023
Aktive Positionen von Miles Nunn
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| AKARI THERAPEUTICS, PLC | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2015 | - |
Karriereverlauf von Miles Nunn
Ehemalige bekannte Positionen von Miles Nunn
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Evolutec Group Plc
 Evolutec Group Plc BiotechnologyHealth Technology Evolutec Group Plc is an biopharmaceutical company, which discovers and develops novel biopharmaceuticals for allergic, anti-inflammatory and auto-immune diseases. It was founded in1998 and headquartered in Oxford, United Kingdom. | Corporate Officer/Principal | - | - |
| Amplion Ltd. | Direktor/Vorstandsmitglied | - | - |
Volution Immuno Pharmaceuticals SA
 Volution Immuno Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Part of Akari Therapeutics Plc, Volution Immuno Pharmaceuticals SA is a Swiss company that develops anti-complement and anti-inflammatory molecules to treat orphan conditions in the autoimmune and inflammatory diseases sectors. The private company is based in Geneva, Switzerland. The company was founded by Raymond Prudo-Chlebosz, who has been the CEO since incorporation. Volution Immuno Pharmaceuticals was acquired by Celsus Therapeutics Plc from RPC Pharma Ltd. on September 18, 2015 for $146.72 million. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2014 | - |
Ausbildung von Miles Nunn
| University of Oxford | Doctorate Degree |
| University College London | Undergraduate Degree |
Statistik
International
| Vereinigtes Königreich | 5 |
| Vereinigte Staaten | 2 |
| Schweiz | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AKARI THERAPEUTICS, PLC | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Volution Immuno Pharmaceuticals SA
Volution Immuno Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Part of Akari Therapeutics Plc, Volution Immuno Pharmaceuticals SA is a Swiss company that develops anti-complement and anti-inflammatory molecules to treat orphan conditions in the autoimmune and inflammatory diseases sectors. The private company is based in Geneva, Switzerland. The company was founded by Raymond Prudo-Chlebosz, who has been the CEO since incorporation. Volution Immuno Pharmaceuticals was acquired by Celsus Therapeutics Plc from RPC Pharma Ltd. on September 18, 2015 for $146.72 million. | Health Technology |
Evolutec Group Plc
Evolutec Group Plc BiotechnologyHealth Technology Evolutec Group Plc is an biopharmaceutical company, which discovers and develops novel biopharmaceuticals for allergic, anti-inflammatory and auto-immune diseases. It was founded in1998 and headquartered in Oxford, United Kingdom. | Health Technology |
| Amplion Ltd. |
- Börse
- Insiders
- Miles Nunn
- Erfahrung
